Skip to main content
Amy Schefler, MD, Ophthalmology, Houston, TX, Houston Methodist Hospital

AmyCScheflerMD

Ophthalmology Houston, TX

Retinal Disease, Ocular Oncology

Retina Consultants of Texas

Dr. Schefler is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Schefler's full profile

Already have an account?

Education & Training

  • University of Miami/Jackson Health System/Bascom Palmer Eye Institute
    University of Miami/Jackson Health System/Bascom Palmer Eye InstituteChief Residency, Ophthalmology, 2009 - 2010
  • University of Miami/Jackson Health System/Bascom Palmer Eye Institute
    University of Miami/Jackson Health System/Bascom Palmer Eye InstituteResidency, Ophthalmology, 2004 - 2007
  • Olive View/UCLA Medical Center
    Olive View/UCLA Medical CenterInternship, Internal Medicine, 2003 - 2004
  • Weill Cornell Medicine
    Weill Cornell MedicineClass of 2003

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 2012 - 2024
  • FL State Medical License
    FL State Medical License 2007 - 2014
  • American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

  • Fellow (FACS) American College of Surgeons

Clinical Trials

Publications & Presentations

PubMed

Authored Content

  • Randomized Trial of Monthly Versus as-Needed Intravitreal Ranibizumab for Radiation Retinopathy-Related Macular Edema: 1 Year OutcomesApril 2020

Press Mentions

  • Aura Biosciences Presents New Preclinical AU-011 Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
    Aura Biosciences Presents New Preclinical AU-011 Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual MeetingMay 3rd, 2021
  • Aura Biosciences Announces Updated Phase 1b/2 Clinical Data for AU-011 Presented at the American Academy of Ophthalmology 2019 Annual Meeting
    Aura Biosciences Announces Updated Phase 1b/2 Clinical Data for AU-011 Presented at the American Academy of Ophthalmology 2019 Annual MeetingFebruary 24th, 2020
  • Light-Activated Agent Novel Option for Uveal Melanoma
    Light-Activated Agent Novel Option for Uveal MelanomaJanuary 15th, 2020
  • Join now to see all

Professional Memberships

Hospital Affiliations